WallStSmart

Health Catalyst Inc (HCAT)vsR1 RCM Inc (RCM)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

R1 RCM Inc generates 715% more annual revenue ($2.46B vs $302.48M). RCM leads profitability with a -2.5% profit margin vs -87.7%. RCM earns a higher WallStSmart Score of 39/100 (F).

HCAT

Avoid

34

out of 100

Grade: F

Growth: 3.3Profit: 2.0Value: 5.0Quality: 4.0
Piotroski: 3/9Altman Z: -3.47

RCM

Hold

39

out of 100

Grade: F

Growth: 6.0Profit: 3.0Value: 5.7Quality: 6.0
Piotroski: 6/9Altman Z: 1.34
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for HCAT.

RCMUndervalued (+26.9%)

Margin of Safety

+26.9%

Fair Value

$19.57

Current Price

$14.31

$5.26 discount

UndervaluedFair: $19.57Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

HCAT1 strengths · Avg: 10.0/10
Price/BookValuation
1.2x10/10

Reasonable price relative to book value

RCM1 strengths · Avg: 8.0/10
Price/BookValuation
2.1x8/10

Reasonable price relative to book value

Areas to Watch

HCAT4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$153.70M3/10

Smaller company, higher risk/reward

Debt/EquityHealth
1.233/10

Elevated debt levels

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

RCM4 concerns · Avg: 2.8/10
PEG RatioValuation
2.064/10

Expensive relative to growth rate

Operating MarginProfitability
3.8%3/10

Operating margin of 3.8%

Return on EquityProfitability
-2.2%2/10

ROE of -2.2% — below average capital efficiency

EPS GrowthGrowth
-99.3%2/10

Earnings declined 99.3%

Comparative Analysis Report

WallStSmart Research

Bull Case : HCAT

The strongest argument for HCAT centers on Price/Book.

Bull Case : RCM

The strongest argument for RCM centers on Price/Book. Revenue growth of 14.7% demonstrates continued momentum.

Bear Case : HCAT

The primary concerns for HCAT are EPS Growth, Market Cap, Debt/Equity.

Bear Case : RCM

The primary concerns for RCM are PEG Ratio, Operating Margin, Return on Equity.

Key Dynamics to Monitor

HCAT carries more volatility with a beta of 1.57 — expect wider price swings.

RCM is growing revenue faster at 14.7% — sustainability is the question.

RCM generates stronger free cash flow (60M), providing more financial flexibility.

Monitor HEALTH INFORMATION SERVICES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

RCM scores higher overall (39/100 vs 34/100) and 14.7% revenue growth. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Health Catalyst Inc

HEALTHCARE · HEALTH INFORMATION SERVICES · USA

Health Catalyst, Inc. provides data and analytics technology and services to healthcare organizations. The company is headquartered in South Jordan, Utah.

Visit Website →

R1 RCM Inc

HEALTHCARE · HEALTH INFORMATION SERVICES · USA

R1 RCM Inc (RCM) stands out as a leading provider of technology-driven revenue cycle management solutions, specifically designed to enhance the financial performance of healthcare organizations across the United States. Leveraging cutting-edge analytics and deep industry insights, R1 RCM optimizes billing processes and boosts operational efficiency for hospitals and outpatient facilities. By maximizing revenue capture while improving patient experiences, the company solidifies its position within a rapidly evolving healthcare landscape. With strategic initiatives aimed at expanding its service offerings and increasing market presence, R1 RCM is poised for sustained growth and a competitive edge in the increasingly complex revenue cycle management sector.

Want to dig deeper into these stocks?